Acquisition Of Workforce And Office Equipment
Total Consideration
$1.0M
ImmunityBio, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$-1
Free Cash Flow Per Share
$-0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity
71.0%
Return on Assets
-79.4%
Return on Invested Capital
40.9%
Current Ratio
5.10
Quick Ratio
5.08
Asset Turnover
0.26
Days Sales Outstanding
137.16
Days Inventory On Hand
441.10
R&D / Revenue
1289.5%
SBC / Revenue
32.5%
Capex / Revenue
3.4%
Working Capital
$253M
Net Current Asset Value
$-687M
Invested Capital
$-500M
OCF / Net Income
0.87
FCF / Net Income
0.88
Accruals Ratio (Sloan)
-9.3%
Net Debt
$-241M
Net Debt / EBITDA
1.00
Interest Coverage
-4.21
Cash Coverage
-5.01
Capex Coverage
-79.29
Tangible Common Equity
$-514M
TCE / Total Assets
-102.5%
Goodwill / Total Assets
0.2%
NOPAT
$-202M
Cash ROIC
62.4%
WC / Revenue
223.4%
Capex / D&A
0.25
Reinvestment Rate
4.6%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
-637.2%
Revenue 5Y CAGR
184.8%
Book Value 5Y CAGR
—
Stock Price (FY-end)
$2
Market Cap
$1.82B
P/S Ratio
16.08
P/B Ratio
—
P/TB Ratio
—
Enterprise Value
$1.58B
EV / Sales
13.95
FCF Yield
-17.0%
Shareholder Yield
-2.0%
Buyback Yield
—
R&D Yield
10.6%
Capex Yield
0.2%
Shares Variation (YoY)
31.3%
Beta (5Y)
2.15
Cost of Equity
15.2%
Cost of Debt (after tax)
2747.0%
52W High
$4
52W Low
$2
Trailing Return 1Y
-28.8%
Trailing Return 5Y
-88.8%
F-Score (Piotroski)
4.00
Z-Score (Altman)
-10.16
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
ImmunityBio, Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 7.20% | 7.00% | 9.50% | 6.80% | 5.20% | 0.00% |
| Foreign Rate Differential | — | — | — | — | — | -0.20% |
| Other Adjustments | -0.20% | -0.90% | 1.50% | 0.30% | -4.50% | -0.20% |
| R&D Tax Credits | -0.10% | 3.70% | -3.60% | -3.10% | -2.50% | -1.10% |
| SBC (Nondeductible) | 1.30% | 0.50% | -0.50% | -1.00% | -1.10% | -3.00% |
| Valuation Allowance Change | -28.20% | -32.70% | -33.00% | -30.20% | -29.70% | -18.70% |
| Tax Law Change | -0.30% | 1.50% | -0.40% | 1.40% | 3.90% | 0.00% |
| Effective Tax Rate | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$1.8M | $9.0K | $34.0K | −$40.0K | — | −$135.0K |
| Income Taxes Paid (Cash) | $8.0K | $9.0K | $2.0K | $8.0K | $15.0K | — |
ImmunityBio, Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Acquisition Of Workforce
Purchase-Price Allocation
Goodwill
$900.0K